<DOC>
	<DOCNO>NCT00004685</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine whether albuterol increase strength patient facioscapulohumeral dystrophy measure quantitative voluntary isometric contraction test . II . Determine whether albuterol increase muscle mass patient population determine 24 hour urinary creatinine excretion dual energy x-ray absorptiometry ( DEXA ) . III . Examine long term safety albuterol patient population .</brief_summary>
	<brief_title>Randomized Study Albuterol Patients With Facioscapulohumeral Muscular Dystrophy</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double blind , placebo control study . Patients randomize one three treatment group . The first group receive placebo . The second group receive low dose albuterol orally every 12 hour . The third group receive high dose albuterol orally every 12 hour . Treatment continue 52 week unless unacceptable side effect occur . All patient return follow assessment week 4 , 12 , 24 , 52 . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Facioscapulohumeral</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Facioscapulohumeral dystrophy Weakness facial muscle , include frontalis , orbicularis oculus , orbicularis oris Weakness scapular stabilizer foot dorsiflexors Weakness grade 2 bad arm use upper extremity grade scale No neuromuscular disease may mimic clinical presentation facioscapulohumeral dystrophy : Ptosis ophthalmoparesis ( congenital strabismus ) Elbow contractures Strictly unilateral weakness Dermatomyositislike skin rash Symmetric distal sensory loss Muscle biopsy finding mitochondrial myopathy , chronic denervation , dermatomyositis , inclusion body myositis , congenital myopathy Electromyographic ( EMG ) finding myotonia , fasciculation , neurogenic motor unit potential Prior/Concurrent Therapy Endocrine therapy : No prior long term use oral corticosteroid 1 year At least 3 month since prior use corticosteroids No concurrent use immunosuppressive agent Surgery : No concurrent surgeries Other : No concurrent use sympathomimetic agent , antidepressant , beta receptor blocker Patient Characteristics Age : 18 80 Performance status : Ambulatory Cardiovascular : No cardiovascular disease , include hypertension coronary artery disease Other : Not pregnant nursing No concurrent uncontrolled medical psychological condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 1999</verification_date>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>muscular dystrophy</keyword>
	<keyword>neurologic psychiatric disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>